Cesar Hernandezto which the Minister Carolina Darias had the good sense to place Director General of the Common Portfolio of Services and Pharmacy for his recognized solvencyYou have a tough job ahead of you. The model for the introduction of medicines in Spain does not satisfy anyone. The main critic is the Ministry of Health itself, which everyone blames for the situation.
Patient organizations and laboratories blame Darias, Hernández and their team for the delay experienced by the arrival of innovative drugs. The latest data from the consulting firm Iqvia place the average delay in 517 days since they received the green light from the regulators, a whole world compared to the stage before the arrival of the PSOE -in 2018 it took 132 days less- and much longer, in any case, than in countries like Germany -133 days-, France –240 days– or England –340 days–. The autonomies, which in the end are the ones that pay for the medicines, and surprisingly, some left-wing associations, blame the Ministry for the opposite. Specific, They reproach him for giving in to pressure from the media and from patient associations, which they see as transmission belts for the interests of the industry. The cases of medicines endorsed by the Price Commission that face all kinds of obstacles before finally landing in hospitals are not rare. Even within communities, there are frequent cases of hospitals that are stricter than others when it comes to administering the drugs. These contradictions get on the nerves of laboratories: despite being exempted in the pandemic from making contributions to public coffers, their products take a world to sell and the parent companies do not understand it.